dimethyl 3-vinyladipate | 39155-18-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dimethyl 3-vinyladipate
• 英文别名: dimethyl 3-vinylhexanedioate；3-Vinyl-adipinsaeure-dimethylester；Dimethyl 3-ethenylhexanedioate
• CAS: 39155-18-5
• 化学式: C₁₀H₁₆O₄
• 分子量: 200.235
• InChiKey: PNBQLFQKMYNPRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl 3-vinyladipate 生成 methyl (1R,2R)-2-ethenyl-5-oxocyclopentane-1-carboxylate
  参考文献：
  名称：

  TOLSTIKOV, G. A.;MIFTAXOV, M. S.;AKBUTINA, F. A, ZH. ORGAN. XIMII, 1983, 19, N 8, 1773-1774

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙烯基环己烷-1,2-二醇 在 草酰氯 、 tris(cetylpyridinium) 12-tungstophosphate 、 双氧水 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 dimethyl 3-vinyladipate
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE
  [FR] COMPOSÉS DE PYRIMIDINE SUBSTITUÉE ET LEURS PROCÉDÉS D'UTILISATION ET DE FABRICATION

  摘要：

  本发明提供了可用于治疗患有疾病或癌症的取代嘧啶化合物。本发明的化合物可用作多酶抗叶酸类药物，选择性地靶向叶酸受体（FR）。此外，还提供了一种制备5-和6-取代环戊[d]嘧啶的方法，用于非经典和经典抗叶酸类药物，作为TS和DHFR抑制剂。

  公开号：

  WO2016022881A1

文献信息

• Substituted Pyrimidine Compounds and Methods of Use and Manufacture
  申请人：Duquesne University of the Holy Spirit

  公开号：US20160039830A1

  公开（公告）日：2016-02-11

  This invention provides substituted pyrimidine compounds having the formula: wherein X is absent, CH 2 , S, or O, and R is an alkyl group having from one to ten carbon atoms, and optionally salts, hydrates, or solvates thereof, that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5- and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.

  本发明提供了具有以下式子的取代嘧啶化合物：其中X为不存在，CH2，S或O，而R是具有从一到十个碳原子的烷基，以及其可选的盐、水合物或溶剂化物，这些化合物在治疗患有疾病或癌症的患者方面是有用的。本发明的化合物可用作多酶抗叶酸剂，有选择性地靶向叶酸受体（FR）。此外，本发明还提供了一种制备5-和6-取代环戊[d]嘧啶用于非经典和经典抗叶酸剂作为TS和DHFR抑制剂的方法。
• Tolstikov, G. A.; Miftakhov, M. S.; Akbutina, F. A., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, # 8, p. 1574 - 1575
  作者：Tolstikov, G. A.、Miftakhov, M. S.、Akbutina, F. A.

  DOI：——

  日期：——
• Structure–Activity Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-microtubule Agent <i>N</i>-(4-Methoxyphenyl)-<i>N</i>,2,6-trimethyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-aminium Chloride and Its Analogues As Antitumor Agents
  作者：Aleem Gangjee、Ying Zhao、Sudhir Raghavan、Cristina C. Rohena、Susan L. Mooberry、Ernest Hamel

  DOI：10.1021/jm400639z

  日期：2013.9.12

  A series of 21 substituted cyclopenta[d]pyrimidines were synthesized as an extension of our discovery of the parent compound (+/-)-1 center dot HCl as an anti-microtubule agent. The structure activity relationship indicates that the N-methyl and a 4N-methoxy groups appear important for potent activity. In addition, the 6-substituent in the parent analogue is not necessary for activity. The most potent compound 30. HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compound (+/-)-1 center dot HCl. In addition, 30 center dot HCl inhibited cancer cell proliferation regardless of Pgp or beta III-tubulin status, both of which are known to cause clinical resistance to several antitubulin agents. In vivo efficacy of 30 center dot HCl was demonstrated against a triple negative breast cancer xenograft mouse model. Compound 30 center dot HCl is water-soluble and easily synthesized and serves as a lead compound for further preclinical evaluation as an
• SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE
  申请人：Duquesne University of the Holy Spirit

  公开号：US20170260190A1

  公开（公告）日：2017-09-14

  This invention provides substituted pyrimidine compounds having the formula: wherein X is absent, CH 2 , S, or O, and R is an alkyl group having from one to ten carbon atoms, and optionally salts, hydrates, or solvates thereof, that are useful in treating a patient having a disease or cancer. The compounds of this invention are useful as multi-enzyme antifolates selectively targeting the folate receptor (FR). Further, a method of making 5- and 6-substituted cyclopenta[d]pyrimidine for nonclassical and classical antifolates as TS and DHFR inhibitors is provided.
• US9650384B2
  申请人：——

  公开号：US9650384B2

  公开（公告）日：2017-05-16